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Abstract
Background: The organisation of vertebrate genomes into topologically associating domains (TADs) is believed to
facilitate the regulation of the genes located within them. A remaining question is whether TAD organisation is
achieved through the interactions of the regulatory elements within them or if these interactions are favoured by
the pre-existence of TADs. If the latter is true, the fusion of two independent TADs should result in the rewiring of
the transcriptional landscape and the generation of ectopic contacts.
Results: We show that interactions within the PAX3 and FOXO1 domains are restricted to their respective TADs in
normal conditions, while in a patient-derived alveolar rhabdomyosarcoma cell line, harbouring the diagnostic t(2;13)
(q35;q14) translocation that brings together the PAX3 and FOXO1 genes, the PAX3 promoter interacts ectopically
with FOXO1 sequences. Using a combination of 4C-seq datasets, we have modelled the three-dimensional organisation
of the fused landscape in alveolar rhabdomyosarcoma.
Conclusions: The chromosomal translocation that leads to alveolar rhabdomyosarcoma development generates a
novel TAD that is likely to favour ectopic PAX3:FOXO1 oncogene activation in non-PAX3 territories. Rhabdomyosarcomas
may therefore arise from cells which do not normally express PAX3. The borders of this novel TAD correspond to the
original 5'- and 3'- borders of the PAX3 and FOXO1 TADs, respectively, suggesting that TAD organisation precedes the
formation of regulatory long-range interactions. Our results demonstrate that, upon translocation, novel regulatory
landscapes are formed allowing new intra-TAD interactions between the original loci involved.
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Background
The advent of chromatin conformation capture technolo-
gies (3C and its variants Hi-C, 5C-seq and 4C-seq;
reviewed in [1]) has been essential in the identification
of megabase-scale chromosomal organisation domains
[2–4], which have been termed topologically associating
domains (TADs). These are large genome intervals de-
fined by an increased number of long-range chromatin
interactions between the loci contained in the same
chromosomal domain and a decreased number of interac-
tions with loci in neighbouring domains [5]. Increasing
experimental evidence suggests that TADs constitute not
only structural but also functional units of the genome.
TADs structurally restrain epigenetic domains [2–4],
domains that can change coordinately in response to ex-
ternal cues [6]. Furthermore, the genome has been divided
into compartments with active or inactive status [7], and
during differentiation, regions subject to repositioning
from one of these compartments to the other correspond
to single or several, consecutive TADs [8, 9]. Therefore,
the genes contained within a TAD, as a group, are more
or less prone to transcription depending on the epigenetic
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state of the domain or the nuclear compartment in which
they are positioned. In fact, genes within TADs do show
gene expression correlation [3, 6], revealing an underlying
mechanism of intra-TAD gene regulation, which does not
necessarily imply that genes included within a TAD are
under the control of the same tissue-specific enhancers.
From an evolutionary point of view, it has been shown
that ancestral recombinations leading to loss of synteny
occur at TAD borders [10], maintaining their structures
and indicating that TADs are under positive selective
forces, most likely because the disruption of a TAD has
deleterious effects on the regulation of the genes within
it. It is still not clear if TADs originate from interactions
between enhancers and promoters within the domain or
if it is this compartmentalisation that permits and re-
stricts enhancer-promoter contacts [11–13].
The molecular nature of TAD borders is still unclear,
although it has been shown that they are enriched in bind-
ing sites for the CTCF protein [2, 3], which has been im-
plicated in three-dimensional (3D) chromatin organisation
and enhancer-blocking activities [14]. The directionality of
the CTCF binding sites seems to be predictive of their
loop-forming activity as deletion or inversion of these sites
results in the generation of inappropriate enhancer-
promoter contacts [15, 16].
A remaining question is how sequence interactions are
restricted to individual domains. The borders between
adjacent TADs seem to restrict cross-border interactions
and thus deletion of these regions results in the mis-
regulation of the genes associated with them. Genome
manipulations of the border separating the Tfap2c and
Bmp7 loci in the mouse show ‘contamination’ of the
transcriptional landscapes of both genes upon inversion
[17], while human disorders such as polydactyly, brachy-
dactyly and F-syndrome have been shown to be related
to the deletion, inversion or duplication of borders sep-
arating the different TADs containing the WNT6-IHH/
EPHA4/PAX3 loci [18], which leads to otherwise prohib-
ited promoter contacts with enhancer elements located
outside their cognate TAD, causing mis-expression of
the genes involved. Analyses of various duplications in
the proximity of the SOX9 locus have shown several out-
comes depending on the exact nature of the duplication:
intra-TAD duplications do not alter overall TAD organ-
isation but may result in increased numbers of intra-
TAD contacts and could give rise to a phenotype; and
inter-TAD duplications that cross TAD borders generate
novel TADs without altering flanking gene expression.
In this second case, a phenotype could arise if the novel
regulatory landscape created by the duplication includes
a coding gene, as it could result in its dysregulation [19].
Thus, the implication is that removal of a border
element results in the fusion of adjacent TADs, while
the inversion/duplication of a border could allow new
regulatory interactions to be formed resulting in in-
appropriate expression of genes around the inversion/
duplication. Importantly, sequences adjacent to the ma-
nipulated borders are also rearranged during the process
and thus a possible contribution to the observed pheno-
types cannot be discarded. Other human chromosomal
rearrangements have been shown to result in the dysreg-
ulation of gene expression by regulatory elements lo-
cated in the proximity of the breakpoints (e.g. [20–26]).
Recurrent chromosomal translocations are formed by
end-joining of two double-strand chromosomal breaks,
which occasionally occur within the introns of individual
genes resulting in the generation of a novel chimaeric
fusion protein harbouring functional domains from the
two proteins and thus new functional properties. In can-
cer, the formation of novel chimaeric transcription fac-
tors, in which the DNA binding domain is encoded by
one gene and the transactivation domain is encoded by
the other, is common. The PAX3:FOXO1 fusion gene,
arising from the t(2;13)(q35;q14) translocation [27] in
the paediatric soft tissue tumour alveolar rhabdomyosar-
coma (ARMS), encodes a transcription factor that con-
tains the PAX3 (paired box 3) DNA-binding domain and
the FOXO1 (forkhead box O1) transactivation domain.
This fusion transcription factor dysregulates PAX3 target
genes resulting in gene expression changes that modify
pathways involved in proliferation and/or survival, con-
tributing to tumour initiation. Translocations involving
PAX3 (or the closely related PAX7) and FOXO1 are only
found in rhabdomyosarcomas. This permits the formula-
tion of two hypotheses: (1) that translocations can occur
in multiple cell types but only those expressing the regu-
latory factors required for the expression of the onco-
gene give rise to rhabdomyosarcomas; or (2) that the
translocations occur in a restricted or unique cell type,
usually by means of co-transcription of the two loci in-
volved in the translocation [28, 29]. Even if this second
hypothesis turns out to be correct, it is still possible that
only those cells that express the correct combination of
transcription factors would give rise to tumour cells as
the fusion gene will be under the transcriptional control
of specific regulatory elements; oncogene activation in a
non-PAX3-expressing cell type may therefore be essen-
tial for the development of the disease. It is thus clear
that unravelling the transcriptional regulatory mecha-
nisms of PAX3, FOXO1 and the oncogenic PAX3:FOXO1
gene should help to identify the elusive cell type of
origin for these sarcomas.
Crucially, we show that the t(2;13)(q35;q14) translocation
in ARMS not only generates a fusion gene but also a novel
fused regulatory landscape that likely controls the expres-
sion of the novel gene. The translocation results in the
formation of a novel TAD structure that retains the 5' and
3' borders of the wild-type PAX3 and FOXO1 TADs,
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respectively. Importantly, interactions between the PAX3
promoter and the FOXO1 region are similar to those estab-
lished by the FOXO1 promoter in its own locus, despite
these regulatory regions being in a completely new regula-
tory landscape. As these interactions are novel, if the estab-
lishment of regulatory interactions were to precede TAD
formation, we would expect a change in TAD boundaries.
Instead, we observe that in the ARMS translocation ana-
lysed, the PAX3 promoter does not interact with sequences
downstream of the original FOXO1 TAD border.
Results
Loss of synteny analyses place the 5' boundary of the
FOXO1/FoxO1 locus in close proximity to its promoter
One of the major unknowns in the study of ARMS is the
nature of the cell that originally suffered the PAX3:FOXO1
chromosomal translocation leading to tumour develop-
ment. We hypothesised that in the translocated chromo-
some the fusion gene would be under the control of both
PAX3 and FOXO1 regulatory elements. For this reason,
we first determined the maintenance of synteny surround-
ing the FoxO1 locus as an approach to establish the exist-
ence of strong constraints on genomic rearrangements as
a proxy for the presence of essential FOXO1 regulatory
regions. With the exception of ray-finned fishes, which
experienced a whole genome duplication (D. rerio, O.
latipes and G. aculeatus; Additional file 1: Figure S1),
and rodents (M. musculus and R. rattus), all species
analysed (mammals, birds, amphibians and reptiles)
share the same chromosomal structure flanking FOXO1
(MRPS31-FOXO1-COG6-LHFP; Table 1), a structure
that has been conserved for at least 450 Mya. The
break of synteny upstream of FoxO1 detected in ro-
dents places the ancestral recombination event in this
group between MRPS31 and FOXO1 (Fig. 1). Analysis
of evolutionarily conserved regions (ECRs) upstream of
mouse FoxO1 shows that a conserved region 47 kb
upstream of the gene maps immediately upstream of
the human MAML3 gene on Chr4, while another ECR,
located 17 kb upstream of mouse FoxO1 maps upstream
of the human FOXO1 gene on Chr 13 (Additional file 1:
Figure S2). This analysis restricts the ancestral recombin-
ation event somewhere in the -17 kb to -47 kb inter-
val upstream of FOXO1.
In the case of the Pax3 locus, the same gene organisa-
tion was found in all species analysed: FARSB-SGPP2-
PAX3-EPHA4. Since no breaks in synteny were ob-
served, no conclusions could be drawn on the span of
Pax3 regulatory elements in the locus but it suggests
that strong evolutionary constrains have maintained this
syntenic block unaltered.
Hi-C and 4C-seq analyses of the PAX3/Pax3 and FOXO1/
FoxO1 loci
We then made use of published Hi-C data on human [2]
and mouse [5] ES cells, which show that the mouse
FoxO1 gene is included within a single TAD (Fig. 2a), as
defined by directionality index analysis (D.I.; 2). Despite
the break of synteny immediately upstream of FOXO1/
FoxO1, the TADs have been maintained in the two species,
with similar upstream and downstream borders indicating
that the ancestral recombination that gave rise to the
Table 1 Location of genes flanking the FOXO1 locus in human Chr13 across species
LHFP COG6 FOXO1 MRPS31
Homo sapiens Chr 13 Chr 13 Chr 13 Chr 13 Human
Macaca mulatta Chr 17 Chr 17 Chr 17 Chr 17 Macaque
Callithrix jacchus Chr 5 Chr 5 Chr 5 Chr 5 Marmoset
Canis lupus familiaris Chr 25 Chr 25 Chr 25 Chr 25 Dog
Monodelphis domestica Chr 4 Chr 4 Chr 4 Chr 4 Opossum
Mus musculus Chr 3 Chr 3 Chr 3 Chr 8 Mouse
Rattus norvegicus Chr 2 Chr 2 Chr 2 Chr 16 Rat
Gallus gallus Chr 1 Chr 1 Chr 1 Chr 1 Chicken
Alligator mississippiensis JH731763 JH731763 JH731763 JH731763 American alligator
Xenopus tropicalis GL172869 GL172869 GL172869 GL172869 Clawed frog
Latimeria chalumnae JH129255 JH129255 JH127414 JH127414 Coalecanth
Danio rerio Chr 10/15 Chr 15 Chr 10/15 Chr 5 Zebrafish
Oryzias latipes Chr 13 Chr 13 Chr 13/14 Chr 14 Medaka
Gasterosteus aculeatus Group I Group I Group I/VII Group VII Stickleback
Callorhinchus milli KI635872 KI635872 KI635872 KI635872 Elephant shark
Gene names are on the top row, animal species on the left column, common names on the right column. In bold, genes mapping to a different syntenic region.
The Coelacanth (L. chalumnae) genome is fractioned at present and thus it is not possible to ascertain if the LHFP/COG6 and FOXO1/MRPS31 scaffolds are
contiguous
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synteny break occurred at the TAD border, as shown for
other loci [10]. PAX3/Pax3 are also located in identical
TADs in the two species, containing the SGPP2 and
FARSB genes and being separated from the EPHA4
regulatory landscape (Fig. 2b). Our analysis shows the
existence of a TAD boundary immediately upstream of
PAX3 in both species. Nevertheless, the Hi-C data reveal
extensive contacts between the two domains separated by
this putative TAD boundary, suggesting these two do-
mains correspond to sub-TAD structures rather than
individual TADs.
We sought to further explore the regulatory landscape
for these genes by performing 4C-seq on 9.5 dpc (days
post coitum) whole mouse embryos using the FoxO1 and
Pax3 promoters as viewpoints. At this developmental
stage, both genes are expressed in a variety of progenitor
and differentiated cells and thus the 4C-seq data represent
an average through different cell types, although overall
TAD organisation is mainly invariant across multiple tis-
sues [2, 30]. The data show that interactions of the mouse
Pax3 promoter are almost equally distributed on either
side (44% and 56%) and mainly restricted to the TAD that
contains it (80.0%), further supporting the hypothesis that
the identified boundary immediately upstream of Pax3
corresponds to a sub-TAD boundary, with Pax3 regula-
tory elements being present in both domains. The mouse
FoxO1 promoter interacts preferentially with downstream
sequences (67.5%), mainly restricted to the TAD (65.6%);
sequences that coincide with H3K27ac active-enhancer
marks (Additional file 1: Figure S3) are detected in multiple
tissues known to express FoxO1 [31].
If FOXO1 enhancer regions are involved in the regula-
tion of the PAX3:FOXO1 fusion gene, then first we had to
gain an insight on the transcriptional regulation of the
FOXO1 gene, identify some of these regions and show that
they might be located downstream of the translocation
breakpoints.
Identification of translocation breakpoints in different
ARMS cell lines
In ARMS, the t(2;13)(q35;q14) translocation occurs be-
tween intron 1 of FOXO1 and intron 7 of PAX3 [32–34].
In order to determine the contribution of putative en-
hancer elements translocated to the derivative t(2;13)
chromosome towards the new regulatory landscape, we
mapped six independent breakpoints in five independent
Fig. 1 ECRs in the FOXO1/FoxO1 loci in relation to human–mouse syntenic regions. ECR output from the ECRBrowser tool (http://ecrbrowser.dcode.org,
2015) showing the positions of evolutionary conserved regions when using (a) the human and (b) mouse genomes as base. Species included in (a):
Chicken, Zebrafish, Xenopus, Opossum, Rat, Mouse, Cow and Dog; species included in (b): Fugu, Xenopus, Chicken, Opossum, Dog, Macaque and Human.
Underneath there is a representation of the synteny blocks between human and mouse with indication of the chromosome in which they are found
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ARMS cell lines harbouring this translocation. A series
of forward primers around 3 kb apart from each other
were designed to span the entire PAX3 intron 7 (18.7 kb)
while a series of reverse primers spaced by ~10 kb was de-
signed to span the entire FOXO1 intron 1 (104.7 kb)
(Additional file 2: Table S1). Forward and reverse primers
were used in all possible combinations in a long-distance
polymerase chain reaction (LD-PCR) designed to amplify
fragments up to 20 kb in length.
Sequence analyses of the SCMC and RH3 breakpoints
showed a seamless transition between PAX3 and FOXO1
loci (Fig. 3a, b), although the exact point of the RH3
breakpoint cannot be ascertained as it occurs at a region
of micro-homology between the two loci (TTA). The se-
quence of the RH5 breakpoint (Fig. 3c) showed a small
amplification of three thymines at the junction between
the PAX3 and FOXO1 loci. The RMS breakpoint (Fig. 3d)
has a 22 bp insertion of a duplicated fragment from
chromosome 13 immediately adjacent to the breakpoint.
Finally, cell lines RH4 and RH41, derived from the same
patient, show the same breakpoint containing a 4.9 kb in-
sertion from chromosome 9 (Fig. 3e). We have previously
reported the identification of the RH30 breakpoint [28].
Identification of regulatory regions driving transcription
of the FoxO1 and Pax3 genes
For FoxO1, three overlapping bacterial artificial chromo-
somes (BACs) were selected from the Children’s Hospital
Oakland Research Institute (CHORI) library: RP23-66C15
(-116 kb to +104 kb, relative to the FoxO1 transcriptional
start site or TSS), RP24-330H17 (-61 kb to +104 kb) and
RP23-96D10 (-38 kb to +148 kb) (Fig. 4a). We introduced
a lacZ reporter gene at the first coding ATG of FoxO1 and
renamed them according to the lengths of their upstream
spans (B116Z-Foxo1, B61Z-Foxo1 and B38Z-Foxo1, re-
spectively). The 5'-end of B38Z-Foxo1 is located within
the interval where the loss of synteny occurs and at the
TAD border, while B116Z-Foxo1 and B61Z-Foxo1, with
almost identical 3'-ends, cross it. We compared the ex-
pression patterns driven by these with that of the Foxo1G-
t(AD0086)Wtsi gene-trap line (Foxo1Gt-β-GEO/+; [31]).
As expected, all of them fail to recapitulate the
complete FoxO1 expression pattern because none of
them contains the full regulatory landscape, which our
4C-seq data indicate spans up to 700 kb downstream of
the gene. Interestingly, the B116Z-Foxo1 BAC con-
struct drives ectopic expression in the neural tube
Fig. 2 FoxO1 and Pax3 promoter interactions are restricted to their respective TADs. (a) FOXO1/FoxO1 and (b) PAX3/Pax3 Hi-C data (2, 5; 20 kb resolution)
coincide with the interactions detected by 4C-seq. The size and position of the FOXO1 and FoxO1 TADs, as determined by D.I. analyses, are very similar
despite the ancestral recombinations that occurred immediately upstream of the genes. Names and positions of the genes in the different loci are
indicated. The transcriptional direction of the different genes is indicated. The percentage of accumulated reads 1 Mb at either side of the FoxO1 and
Pax3 promoters and within the TADs are shown. In the human genome, the positions of the calculated borders for (a) the FOXO1 locus are (left to right)
Chr13: 41,902,000; Chr13: 41,362,000; Chr13: 40,262,000 and Chr13: 39,502,000 and for (b) the PAX3 locus are (left to right) Chr2: 223,817,756; Chr2: 223,511,756;
Chr2: 223,171,756 (sub-TAD boundary); Chr2: 222,871,756 and Chr2: 222,451,756
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(Fig. 4b). Unlike B61Z-Foxo1, which also crosses the
TAD border, B116Z-Foxo1 contains regions with strong
active-enhancer marks in several tissues including some
pertaining to the central nervous system. Thus, in this
context, the sequence underlying this TAD border does
not possess intrinsic transcriptional boundary activity
per se because it is unable to block the interactions
between regulatory elements and the promoter when
placed in between them. Except for this remarkable
difference, B61Z-Foxo1 and B116Z-Foxo1 drive very
similar expression patterns from 9.5 dpc to the adult
(note that their 3'-ends are almost identical; compare
Additional file 1: Figures S4 and S5). Sites of expression
include the myotome, fore-gut and hind-gut diverticula,
the stomach, the apical ectodermal ridge (AER), limb,
thoracic and facial skeletal muscle, the inner layer of
the retina, the posterior wall of the lens vesicle, and the
nasal pits. In contrast, the B38Z-Foxo1 construct drives
expression from 9.0 dpc in vascular precursors
throughout the embryo (Fig. 4b and Additional file 1:
Figure S6). This finding indicates that a regulatory
module for vasculature expression maps in the non-
overlapping region between B61Z-Foxo1/B116Z-Foxo1
and B38Z-Foxo1, that is, +104 to +148 kb from the
FoxO1 TSS. Time course analyses of these transgenic
lines revealed that all three constructs fail to recapitu-
late the complete FoxO1 expression pattern (e.g. no
expression is observed in brown adipose tissue -BAT-
from 16.5 dpc onwards in any of the lines), indicating
that the enhancer(s) responsible to drive BAT expres-
sion is not contained within these BAC clones.
In order to analyse Pax3 gene expression, several BAC
clones were identified from the CHORI library; for this
study we selected RP23-260 F1 (end-sequences Gene-
Bank accession numbers: AQ927932 and AQ927929).
This BAC carries 30 kb and 135 kb of sequences
upstream and downstream of the transcriptional start
point of Pax3, respectively (Additional file 1: Figure
S7a). Thus, the BAC is completely embedded within the
TAD although it crosses the putative sub-TAD border.
This BAC was modified by the introduction of a nlacZ-
SV40pA cassette at the translational start point of Pax3
(construct B30Z-Pax3) and used to generate transgenic
lines. The transgene closely follows the endogenous
Fig. 3 Mapping ARMS translocations to the base pair level. Sequence tracks of the translocation breakpoints identified in five independent ARMS
cell lines: (a) SCMC, (b) RH3, (c) RH5, (d) RMS and (e) RH41. In three cases, the translocation produces a clean cut between Chr2 (yellow) and Chr13
(purple) sequences. e In the RH41 cell line there is a clean insertion of a 4.9 kb fragment from Chr9 (red). The genome positions of the translocation
breakpoints are provided (hg19). f Detail of the ECR Browser output (Chicken, Opossum, Mouse, Cow; base genome, Human) covering the genomic
interval between exons 6 and 8 of PAX3 showing the precise location of the mapped translocation breakpoints in intron 7. g Detail of the ECR Browser
output covering the genomic interval between exons 1 and 2 of FOXO1 showing the location of the mapped translocation breakpoints in intron 1
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pattern of Pax3 [35], being expressed in the neural tube,
neural crest cells, somites, the hindbrain, the midbrain
and forebrain, migrating limb and hyploglossal chord
muscle precursors, the pre-somitic mesoderm, trigem-
inal ganglia and the lateral nasal process (Additional
file 1: Figure S7b).
We generated additional lines using another BAC
construct carrying 14 kb upstream of the Pax3 trans-
lational start site and 128 kb downstream of it
(RP24-235I14). Analysis of transgenic animals carry-
ing B14Z-Pax3 (Additional file 1: Figure S7c) shows
an identical pattern of expression to that driven by
the B30Z-Pax3 described above. Therefore, the ma-
jority of the regulatory elements needed for the cor-
rect spatiotemporal expression of Pax3 during embryonic
development are presumably contained within this
BAC.
Identification of regulatory regions downstream of the
RH30 translocation breakpoint
We wanted to examine the enhancer potential of
sequences situated downstream of the translocations in
ARMS and for this we generated a new BAC construct
in which all sequences downstream of the translocation
breakpoint found in the RH30 cell line were deleted
(B38Z-Foxo1-RH30Δ). We selected this particular break-
point because the new regulatory landscape generated
by the translocation in the RH30 cell line putatively
carries more PAX3 and FOXO1 regulatory elements
than the other cell lines analysed. Comparison of the
expression patterns driven by the B38Z-Foxo1, B61Z-
Foxo1 and B38Z-Foxo1-RH30Δ (Fig. 5a) in transgenic
embryos shows that both the myotomal and embryonic
vascular enhancers are located downstream of the RH30
translocation, as B38Z-Foxo1-RH30Δ only drives
Fig. 4 Crossing the TAD border can drive ectopic transgene expression from enhancers in the adjacent domain. a Detail of the Hi-C data from
mouse ES cells at the TAD border (green box). H3K27ac marks in different mouse tissues are shown underneath, as well as the position of the two
coding genes in the region and the relative positions of the three BAC clones used in the study. The 5' ends of the clones cross the TAD border,
although in the case of B38, its end maps within the border region. There are strong active-enhancer marks in the non-overlapping region between
B116 and B61. b Expression patterns of Foxo1Gt-β-GEO/+, B38Z, B61Z and B116Z at 9.5 dpc. B116Z drives strong expression in the CNS, while B61Z does
not; B38Z drives strong vascular expression like the gene-trap allele. D.I. directionality index
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expression in the AER, the foregut and the stomach. This
allows the generation of a preliminary map (Fig. 5b) for
the location of enhancer elements in relation to the RH30
translocation, which shows that while the enhancer ele-
ments driving expression in the developing fore-gut and
hind-gut, the stomach and the AER are located upstream
of the RH30 translocation, at least two major enhancers
are located downstream of this translocation breakpoint.
It is also important to highlight other sites of FoxO1 ex-
pression in the mouse (e.g. brown adipose tissue or BAT),
not observed in our transgenic lines but detected in a gene
trap mouse strain [31], indicating that the regulatory ele-
ments controlling the expression at these other sites are
not located within the BACs analysed, but further down-
stream. Thus, in the translocated chromosome, the PAX3
promoter is in close proximity, at least in the linear
genome, to enhancers active in non-PAX3 territories (e.g.
embryonic vasculature and BAT).
Deletion of the sequences downstream of the RH30
translocation breakpoint from B30Z-Pax3 (construct
B30Z-Pax3-RH30) has a very limited effect on the
overall expression pattern (Fig. 5c), with some changes
in intensity levels at some locations. This result sug-
gests that most, if not all, PAX3 regulatory modules will
be carried by the derivative t(2;13)(q35;q14) chromo-
some following the translocation event.
Fused regulatory landscape in ARMS
We hypothesised that the translocation event would
generate a fusion of the regulatory landscapes defined by
the upstream and downstream boundaries of PAX3 and
FOXO1, respectively (Fig. 2). This new regulatory land-
scape would therefore allow the interaction of the PAX3
promoter with FOXO1 regulatory sequences and drive
the expression of the oncogene in non-PAX3 territories.
To test this, we performed 4C-seq using chromatin from
the patient-derived cell line RMS taking viewpoints scat-
tered throughout the PAX3:FOXO1 fused locus (Fig. 6a).
Some of them correspond to CTCF binding sites (VP1,
VP2, VP6, VP8 and VP9), while others coincide with ECRs
(VP4, VP5, VP7). Specifically, VP4 marks a well-known
PAX3 enhancer that drives neural crest expression [36].
Functional activity of the other two ECRs has not been de-
termined, but they are enriched in active chromatin marks
in various tissues. VP3 corresponds to the PAX3 pro-
moter. 4C-seq data were integrated to create virtual 3D
chromatin conformation models (Additional file 3: Movie
S1), which were further converted into a virtual Hi-C
heatmap (Fig. 6b), as previously described [37]. As an ex-
ample, one of the virtual models generated is represented
in Fig. 6c and d and Additional file 4: Movie S2.
As predicted, the chromosomal rearrangement that
takes place in RMS cells generates a new TAD as the
result of the fusion of PAX3 and FOXO1 regulatory land-
scapes. Importantly, the borders of this new TAD coincide
with those calculated in the wild-type loci (compare the
positions of the borders in Figs. 2 and 6). Furthermore,
these translocation TAD borders are mainly invariant
across a multitude of human tissues (Additional file 2:
Table S2), the upstream PAX3 border and the downstream
FOXO1 border being conserved at a +/– 20 kb resolution
in 61.9% and 66.7% of the 21 cell types/tissues analysed,
respectively [30]. Thus, the new TAD harbours the PAX3:-
FOXO1 fusion gene, as well as FARSB and SGPP2, while
the flanking TADs remain mainly unchanged, with the ex-
ception of the boundary at the end of the analysed region,
which shows a significant difference. Nevertheless, as this
particular predicted boundary is at the end of the analysed
region, it may arise as an artefact of the computational ap-
proach, which is not reliable at the extremes. Interestingly,
the 4C-seq data indicate that these flanking TADs interact
with each other (note the rhomboid-like domain above
the PAX3-FOXO1 TAD in Fig. 6b), presumably reinforcing
the formation of an isolated highly self-interacting domain
in between them. Although the D.I. analysis of the virtual
Fig. 5 Pax3 and FoxO1 enhancers located downstream of the RH30
breakpoint. a At 11.5 dpc, B38Z-Foxo1 drives expression in the
embryonic vasculature, a hindlimb rostral domain, AER, stomach
and gut. Myotomal expression is faint and masked by the vascular
expression; B61Z-Foxo1 expresses in all these domains excluding
the vasculature; B38Z-Foxo1-RH30Δ is not able to drive vascular or
myotomal expression. b Map showing the position of enhancer regions
identified downstream of the RH30 translocation breakpoint. The three
BAC clones are represented as black bars with their given names.
Different coloured boxes represent the location of different enhancer
regions within the BACs. c Deletion of sequences downstream the
RH30 breakpoint in B30Z-Pax3 do not result in a pattern change
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Hi-C data does not reveal the existence of the predicted
sub-TAD containing SGPP2 (as observed in the Hi-C
analyses of wild-type mouse and human loci), the 3D chro-
matin structure model clearly shows an isolated chromo-
somal loop that contains the SGPP2 promoter (Fig. 6d and
Additional file 3: Movie S1; Additional file 4: Movie S2).
The human PAX3 promoter is able to interact with
potential FOXO1 enhancers in RMS cells
Having demonstrated that the PAX3 promoter lies in the
same domain as FOXO1 regulatory elements in the
translocated chromosome, we sought to determine if, in-
deed, they could interact with each other to drive the
expression of the oncogene in FOXO1-specific tissues.
For this reason, we focused on the 4C-seq data that
take the human PAX3 promoter as a viewpoint and
detected strong interactions between the PAX3 pro-
moter and FOXO1 regions situated downstream of
the identified breakpoint in the RMS cell line (Fig. 7).
The first ectopic contacts on the FOXO1 locus occur
immediately downstream of the defined breakpoint,
strengthening further our breakpoint mapping strategy.
Fig. 6 Virtual-HiC of the PAX3-FOXO1 locus in RMS cells predicts the generation of a new TAD. a 4C-seq profiles using nine different viewpoints
(VP1–VP9) spanning 3.5 Mb. The locations of the viewpoints are indicated above the graph. The location of the fusion PAX3:FOXO1 gene and other
coding sequences is indicated, as well as the position of the RMS breakpoint. Green and orange boxes indicate reads mapped to Chr2 or Chr13,
respectively. b The virtual-Hi-C generated from the 4C-seq data was subjected to a D.I. analysis to determine the location of TAD borders. The
upstream and downstream borders thus defined closely match those obtained by D.I. analyses of human Hi-C data while a novel TAD encompassing
the PAX3-FOXO1 fusion locus is predicted. The positions of the viewpoints (pale green circles), the promoters of the genes in the region (coloured
hexagons) and the borders identified by D.I. analysis (coloured boxes) are indicated. The chromosomal coordinates of the predicted borders are
provided underneath. 3D chromatin architecture model for the locus encompassing the translocation in ARMS, (c) showing the contribution of
both chromosome regions to the predicted new TAD and (d) the location of promoter sequences within the TAD
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Furthermore, the span and location of the interactions
of the PAX3 promoter with the FOXO1 locus in the
translocation closely match those detected by 4C-seq
in the mouse locus (Fig. 7c and d), suggesting that
the FOXO1 region within the novel TAD is folded in
a structure similar to that of the wild-type FOXO1
locus in chromosome 13; it is within this new chro-
matin structure that interactions between FOXO1
regulatory elements and the PAX3 promoter take
place. We then applied a peak-calling algorithm that
was able to detect 24 interaction peaks from the
translocation point to the TAD border (Additional file
1: Figure S8 and Additional file 2: Table S3). Many of
these peaks (16/24) are enriched in active chromatin
marks in a variety of tissues known to express FOXO1,
including skeletal muscle, adipose nuclei and endothe-
lial cells. Also, some of them contain ECRs (5/24), as
well as experimentally validated (ChIP-seq) binding
sites (14/24) for specific transcription factors (e.g.
EP300, MEF2A or CEBPB) or structural proteins such
as CTCF and RAD21 (9/24). Together, these data sug-
gest that the PAX3 promoter engages in interactions
with potential FOXO1 regulatory elements in the trans-
located chromosome in ARMS tumours, interactions
that are restricted to the wild-type 3' TAD border of
the FOXO1 locus.
Fig. 7 The PAX3 promoter interacts with FOXO1 sequences in a patient-derived ARMS cell line. 4C-seq profiles on (a) the PAX3 and (b) the PAX3-
FOXO1 loci obtained using the PAX3 promoter as a viewpoint in the RMS cell line. The locations of the promoter and the translocation breakpoint
in are indicated. In (b), the first row represents the derivative t(2:13) chromosome 4C-seq profile. Green and orange boxes indicate reads mapped
to Chr2 or Chr13, respectively. The second row shows the location of the fusion PAX3:FOXO1 gene and other coding sequences. The third row indicates
the locations of 4C-peaks defined using the Peak Calling algorithm; the downstream limit was taken as the TAD boundary defined in the previous
experiment. The fourth and fifth rows show H3K4me1 and H3K27ac marks in different tissues, respectively. The sixth row is the transcription factor-ChIP
track from UCSC. The seventh row indicates vertebrate conservation. c Sequence-paired 4C-seq tracks on the FOXO1/FoxO1 locus from mouse embryos
(green) and the RMS cell line (red) showing the location of ECRs shared between human, mouse and opossum genomes as shown in Additional file 1:
Figure S3. d Correlation between the 4C-seq signal in the FOXO1/FoxO1 loci from mouse embryos and RMS human cells. For each conserved element,
the 4C-seq signal in human cells corresponding to this region is plotted against the 4C-seq signal from mouse embryos in the orthologous region.
The red dashed line represents the linear regression line
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Discussion
Transcriptional regulation of FOXO1 and PAX3
The transgenic analyses show that FoxO1 is regulated by
individual regulatory regions driving expression of the
transgene in different anatomical locations during embry-
onic development and in the adult. Importantly, we have
mapped the enhancer responsible for embryonic vascular
expression to the non-overlapping region between B61Z
and B38Z (the +104 kb to +148 kb interval), downstream
of exon 2 and thus located downstream of all translocation
breakpoints in ARMS. None of our constructs is able to
direct expression in brown adipose tissue (BAT), a strong
site of expression for the endogenous FoxO1 [31], indicat-
ing that this element is located further downstream.
In the case of Pax3, differences in the relative intensity
of expression between neural tube and somites probably
arise from the perdurance of β-galactosidase activity, as
noted for other lacZ transgenes [38], and the existence
of a micro RNA sequence in the 3'UTR of Pax3 [39, 40]
that downregulates somitic expression but cannot act on
our lacZ construct as it is terminated by the SV40pA
sequence. The fact that B14Z-Pax3 contains the 14 kb
interval previously described [41] as the only required
sequences upstream of the Pax3 gene and that it can
drive most, if not all, of the Pax3 endogenous pattern
during early embryonic development, suggests that
most of the embryonic Pax3 regulatory elements are
located downstream of the Pax3 translational start
site.
Structural organisation of the PAX3:FOXO1 locus in ARMS
Our synteny analysis shows that the chromosomal struc-
ture that includes the FOXO1 locus (LHFP-COG6-
FOXO1-MRPS31) is highly conserved between species as
evolutionary distant as the cartilaginous fish Elephant
shark (Callorhinchus milii) and humans, revealing that
the same gene structure flanking the FOXO1 gene has
been maintained at least over the past 420 Mya. We
propose that the localisation of the FOXO1 promoter in
close proximity to the upstream TAD border has been
the driving force for the invariant structure of that
border. Indeed, a single break of synteny could be identi-
fied in all the species covered by our analysis and that
arose following a chromosomal rearrangement at the
base of the rodents precisely at the interface between the
two TAD structures.
Other changes in the genomes of teleosts also took
place following the whole genome duplication event at
the base of the bony fish group following chromosomal
rearrangements. In the three cases analysed, the struc-
ture of the syntenic region has also been maintained
and the FOXO1-COG6-LHFP syntenic group retained.
Interestingly, the original upstream structure has also
remained on the paralogous gene, indicating the presence
of strong constraints for the disaggregation of these genes
and their regulatory sequences, even if duplicated.
The study of oncogenic recurrent chromosomal trans-
locations allows investigation of the effects of chromo-
somal rearrangements on gene expression without the
need to resort to the reconstruction of the effect of
evolutionary forces upon the process.
We have shown that in ARMS, the PAX3 promoter in-
teracts strongly with sequences in the FOXO1 locus,
sequences and interactions that are conserved in the
wild-type mouse locus and that, in many cases, correlate
with the presence of H3K27Ac marks, DNAseI hyper-
sensitive sites, the binding of diverse transcription
factors, and ECRs, indicative of active enhancers. This
implies that the PAX3:FOXO1 oncogene is, at least in
part, under the control of FOXO1 regulatory elements.
Furthermore, the profile of interactions between the
PAX3 promoter and FOXO1 sequences correlates with
the profile of interactions observed between the mouse
FoxO1 promoter and its regulatory landscape.
The chromatin extrusion model of TAD formation
[42, 43] may explain how the borders flanking the fused
TAD are conserved after the translocation. According
to this model, loop-extruding factors (likely, cohesins)
would load randomly onto the DNA forming a small
chromatin loop. Then, these factors would slide
through the chromatin in opposite directions while still
tethered, progressively extruding the DNA between
them creating a larger loop. Once they encounter a
boundary element (likely, CTCF in a specific orienta-
tion), they would be stalled. The new TAD would thus
be formed by the interaction between the pre-existing
borders creating a new regulatory landscape in which
contacts between the PAX3 promoter and regulatory
elements of FOXO1 take place. We cannot exclude that
these interactions may contribute to the formation and/
or maintenance of the new TAD, as previously sug-
gested in the case of the Xist locus [44].
TADs are composed of and are a consequence of chro-
matin interactions. However, in the case of the PAX3:-
FOXO1 TAD we argue against a model in which TAD
formation is caused by the pre-establishment of specific
enhancer-promoter or enhancer-enhancer regulatory
interactions. The translocation places the PAX3 promoter
and enhancers from both genes in a new regulatory envir-
onment. We would argue that in this new environment
the interactions would be significantly different from those
established in the wild-type locus and thus if these pre-
ceded TAD organisation, a shift of the position of the bor-
ders would have been observed.
It has recently been reported that active transcription
or gene looping is not required for TAD formation [45].
The authors show conservation of TAD organisation
around the CFTR locus in five different cancer cell lines,
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two of which do not express the gene. Furthermore,
looping interactions within the CFTR-containing TAD
(intra-TAD interactions) were highly specific in those
cells that express the gene and absent in those that
do not express it. Thus, as previously reported [2,
46], internal TAD organisation is cell-type specific
whereas overall TAD structures are mostly conserved,
which argues against a model in which TADs are pas-
sively formed as a consequence of the establishment
of specific regulatory interactions. Additionally, such a
model in which the emphasis is placed on the inter-
actions and not on the importance of a border would
not explain why the removal of TAD boundaries cause
adjacent TADs to merge and a rewiring of regulatory
interactions [17–19].
Our analyses also show that while both B61Z- and
B116Z-Foxo1 cross the FoxO1 5'-TAD border, only
B116Z-Foxo1 spans into regions marked by H3K27ac in
the whole brain, cerebellum and olfactory tract, which
suggest the presence of active neural tissue enhancers.
Therefore, the sequence of this TAD border is not suffi-
cient to separate regulatory landscapes, indicating that
efficient separation may require interaction between
TAD-border sequences, such as convergent CTCF bind-
ing sites [15, 16], and other sequences within the TAD
domains. In fact, close observation of the mouse Hi-C
data reveals that the borders of the FoxO1-containing
TAD do interact with each other (note the interactions
at the peak of the triangle depicting the third TAD at
the bottom of Fig. 2a).
Implications for the cell type of origin for ARMS
ARMS tumours appear generally in trunk and extremities
[47], but examples of other sites of primary ARMS abound
in the literature (e.g. [48–53]), suggesting that they can
arise in multiple cell types or in a single cell type found
throughout the body, with certain locations such as the
extremities being more susceptible than others. ARMS
tumours are characterised by the expression of muscle-
specific markers (reviewed in [54]), suggesting a possible
myogenic origin, although their molecular characteristics
are more related to cells that have been committed to the
myogenic lineage but are unable to complete terminal dif-
ferentiation to become skeletal muscle. For example, it
has been shown that MYOD is activated by the PAX3-
FOXO1 fusion protein while it interferes with its chroma-
tin remodelling functions, inhibiting the expression of the
skeletal muscle terminal differentiation factor, MYOG
[55]. An interesting hypothesis is that dysregulation of
PAX3 or PAX7 target genes may result in the activation of
the myogenic programme in a non-myogenic lineage, the
cells being able to transdifferentiate but unable to fully
complete terminal differentiation. It has been shown that
ectopic expression of PAX3 in the lateral plate mesoderm
of chick embryos induces the expression of the myogenic
regulatory factors MYF5, MYOG and MYOD [56]; expres-
sion in mesenchymal stem cells also induces the activation
of myogenic markers such as MYF5, MYOD, MYOG,
MCK and MHC, pushing them towards the myogenic
lineage, while blocking their osteogenic, chondrogenic or
adipogenic potential [57]. It is thus likely that the
myogenic-like transcriptome of ARMS tumours [58] is the
result of PAX3:FOXO1 activation rather than a remnant of
their lineage origin.
Several cell types have been previously suggested as the
origin for ARMS, corresponding to embryonic, postnatal
or adult stem cells or adult myofibres [59], both from the
myogenic lineage [60–64] or other lineages [65, 66].
Our data reveal a clear set of interactions in the em-
bryo between the FoxO1 promoter and, in the RMS cell
line, the PAX3 promoter, and far-downstream sequences
in the FOXO1/FoxO1 locus, which presumably corres-
pond to enhancer regions of the gene.
An interesting site of FoxO1 expression is BAT [31],
which can easily transdifferentiate into muscle and vice
versa [67–70], while overexpression of a constitutively ac-
tive Smoothened restricted to adipocytes has been shown
to give rise to embryonic rhabdomyosarcomas (ERMS)
[71] with relative high penetrance.
None of our constructs drive expression in BAT, indicat-
ing that the enhancer(s) responsible for this aspect of the
expression is located even further downstream. Indeed,
epigenetic marks in BAT from 24-week-old mice indicate
active sites coincident with downstream regions that
interact strongly with both the mouse FoxO1 and human
PAX3 promoters (Additional file 1: Figure S3), while our
data clearly show that the enhancers required for both
embryonic and adult vasculature expression are located
downstream of all the mapped translocation breakpoints.
Another important site of expression is the developing
and adult vasculature, although we have not identified
the different cell types associated with this expression.
In the embryo, some progenitors for vasculature and
skeletal muscle reside in the dermomyotome and their
fate decision depends on the ratio between Pax3 and
Foxc2, acting as pro-myogenic and pro-angiogenic fac-
tors, respectively. Importantly, Foxc2 expression is re-
pressed both by PAX3 and the PAX3-FOXO1 fusion
protein, promoting myogenesis in cells that, under nor-
mal circumstances, would not give rise to skeletal
muscle [72]. Therefore, we propose the BAT and vascu-
lature cell lineages as new candidates for the cell type of
origin for ARMS. As the survival rates for these types
of tumour are particularly low (around 70% of pa-
tients show recurrent tumour resurgence following
current therapies), the final identification of the line-
ages that can serve as origin for ARMS will provide
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further information on the biology of these tumours
and the importance of additional activating mutations
specific for each lineage, opening new avenues for the
development of new targeted therapies based on the
transcriptome and epigenome of the individual cell
types of origin.
Conclusions
We have shown that novel regulatory landscapes arise as
a result of oncogenic human translocations and that
these are restricted by the original upstream and down-
stream TAD boundaries of the genes involved in the
translocation, indicating that TAD formation precedes
intra-TAD interactions. We have identified several major
enhancer regions for FOXO1 present downstream of all
t(2;13) translocations in ARMS and thus potentially able
to drive expression of the oncogene in non-PAX3-
expressing cells. We also indicate that brown adipose
tissue and the vasculature should be considered in future
studies on cell lineage of origin for ARMS. Ectopic onco-
gene activation may be an essential step in the tumori-
genic process, as expression in a particular cell type, the
often-elusive cell of origin, may be required for disease
development.
Methods
Integration of a LacZ reporter gene into BAC clones
To target the FoxO1 BACs, homology arms were synthe-
sised by standard PCR methods using the oligonucleotide
primers pFoxHAF +ApaI/pFoxHAR+ApaI (Additional
file 2: Table S1) which generate a 410 bp fragment span-
ning 204 bp and 206 bp upstream and downstream of the
first coding ATG of FoxO1, respectively. We then used the
single NcoI site at position -1 to insert a linker sequence
(Additional file 2: Table S1). Into the single BglII of the
linker we then cloned a galK selectable marker [73] or a
~3 kb BamHI fragment from our standard construct #1
[74] containing a nuclear-localised lacZ reporter gene and
a SV40 polyadenylation signal. To target the Pax3
BACs, homology arms were synthesised by standard
PCR methods using the oligonucleotide primer pairs
pPax3_5HAF + EagI/pPax3_5HAR + Link and pPax3_3-
HAF + Link/pPax3_3HAR + EagI (Additional file 2:
Table S1) and then joined by PCR. This generates a
950 bp fragment spanning 461 bp and 468 bp upstream
and downstream of the first coding ATG of Pax3, re-
spectively, and introduces a small polylinker immedi-
ately upstream of the gene. We then used the single
BglII site at position -1 to insert the galK selectable
marker or the nuclear-localised lacZ reporter gene and
a SV40-polyA. These constituted the targeting cassettes.
The B116-Foxo1, B61Z-Foxo1, B38Z-Foxo1, B14-Pax3
and B30-Pax3 BAC constructs were then modified by
two-step galK recombineering [73] with modifications as
previously described [75]. All positive clones were checked
for integrity by multiple restriction digests and inserts
sequenced prior to pronuclear injection. The number of
independent transgenic lines showing similar expression
patterns for each construct is as follows: B38Z-Foxo1: four
lines; B61Z-Foxo1: three lines; B116Z-Foxo1: three lines;
B14Z-Pax3: two lines; B30Z-Pax3: four lines.
RH30 deletion in BAC clones
To generate the deletions at the RH30 breakpoint se-
quence in mouse BACs, we made homology cassettes
(Additional file 2: Table S1) with ~75 bp of homology at
either side of the mouse sequence corresponding to the
breakpoint in the RH30 cell line and containing a
LoxP511 site in the same orientation as the one in the
BAC vector-backbone (pBACe3.6). The cassettes were
then inserted by single-step recombineering [73] in
B38Z-Foxo1 and B30Z-Pax3. Positive clones were se-
quenced and transferred into the SW106 E. coli bacterial
strain [73] that carries an Arabinose-inducible Cre gene
for the excision of the intervening fragments. Following
induction of Cre expression, positive clones were identi-
fied and checked for integrity by multiple restriction
digests; deletions were confirmed by sequencing prior to
pronuclear injection. The number of independent trans-
genic lines showing similar expression patterns for each
construct is as follows: B38Z-Foxo1-RH30Δ: three lines;
B30Z-Pax3-RH30Δ: two lines.
Generation of transgenic mice and embryo analyses
BAC DNA was prepared using the QIAgen maxiprep kit
(QIAGEN Ltd., UK) as previously described [75]. After
dialysis against microinjection buffer (10 mM Tris-HCl
pH 7.5, 0.1 mM EDTA pH 8.0 and 100 mM NaCl), DNA
was diluted to 1.6–1.8 ng/mL in microinjection buffer and
used for pronuclear injection of fertilised mouse eggs from
B6CBAF1/OlaHsd crosses using standard techniques. Em-
bryo β-galactosidase staining was performed as previously
described [75]. Embryo pictures were obtained using a
Nikon SMZ1500 microscope and a JVC KY-F55B 3-CCD
camera connected to a Scion Series 7 card. Images were
imported into AdobePhotoshop (v12.0 x64) and whole
image correction applied using the ‘AutoLevels’ tool.
Identification of breakpoints in ARMS cell lines
The RH3, RH28 and RH41 cell lines were obtained from
Dr Peter Houghton (St Jude Children’s Research Hos-
pital, Memphis, TN, USA); the RMS, SCMC and RH30
cell lines were a kind gift from Dr Janet Shipley (The In-
stitute of Cancer Research, Sutton, UK). Cells were
grown in Dulbecco’s Modified Eagle’s Medium (DMEM,
SIGMA UK) supplemented with 10% (v/v) fetal calf
serum, 60 mg/mL Benzylpenicillin and 100 mg/mL
Streptomycin sulphate. Cells were isolated from two
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75 cm2 flasks (Nunc) at 80% confluency by standard
methods and genomic DNA extracted as previously
described [76]. LD-PCR was used to amplify the gen-
omic DNA from the different cell lines using all possible
combinations from 11 oligonucleotides evenly spaced
over ~110 kb and covering intron 1 of FOXO1 (Foxo1-
LD primers) and seven oligonucleotides evenly spaced
over ~27 kb and covering intron 7 of PAX3 (Pax3-LD
primers) (Additional file 2: Table S1). LD-PCR was per-
formed using the Expand Long Template PCR kit
(Roche), using Buffer 3, as instructed by the manufac-
turers. The SCMC breakpoint was amplified with the
Foxo1-LD8/Pax3-LD6 primer pair (3.1 kb); the RH3
breakpoint was amplified with the Foxo1-LD8/Pax3-LD2
primer pair (1.3 kb fragment); the RH5 breakpoint was
amplified using the Foxo1-LD8/Pax3-LD3 primer pair
(5.3 kb); the RMS breakpoint was amplified using the
Foxo1-LD5/Pax3-LD3 primer pair (7.8 kb); the RH4/
RH41 breakpoint was amplified using the Foxo1-LD7/
Pax3-LD3 primer pair (12.8 kb fragment). Products were
cloned into pCR2.1-TOPO (Invitrogen) and sequenced.
We have previously reported the sequence of the RH30
translocation breakpoint [28].
4C-seq analyses
4C-seq assays were performed as previously reported
[77–80]. Briefly, hybrid CBA/C57Bl6 mouse embryos at
the desired stage were disrupted using 1X PBS/0.125%
(w/v) collagenase (Sigma-Aldrich). 107 individual cells
were fixed in 1X PBS/2% (w/v) formaldehyde for 15 min
at room temperature. A total of 155 μl of 10% (w/v) Gly-
cine were added to stop the fixation, followed by a wash
by centrifugation with 1X PBS at 4 °C. Pellets were fro-
zen in liquid nitrogen and kept at -80 °C. Isolated cells
were lysed (lysis buffer: 10 mM Tris-HCl pH 8, 10 mM
NaCl, 0.3% (v/v) IGEPAL CA-630 [Sigma-Aldrich]), 1X
protease inhibitor cocktail (cOmplete, Roche) was
added and the DNA digested with DpnII and Csp6I
as primary and secondary enzymes, respectively. T4
DNA ligase was used for both ligation steps. Specific
primers were designed at the genes promoters 4C-
mPax3 (mouse Pax3 promoter), 4C-hPAX3 (human
PAX3 promoter) and 4C-mFoxo1 (mouse FoxO1 pro-
moter), as well as for the rest of the viewpoints
(VP1–VP9) (Additional file 2: Table S1) with Primer3
(v. 0.4.0) [81]. Illumina adaptors were included in the
primer sequences. Eight separate PCRs were per-
formed for each viewpoint with Expand Long Tem-
plate PCR System (Roche) and pooled together. The
libraries were purified with a High Pure PCR Product
Purification Kit (Roche), concentrations measured
using the Quanti-iTTM PicoGreen dsDNA Assay Kit
(Invitrogen) and sent for deep sequencing.
4C-seq data analyses and 3D chromatin modelling
4C-seq data were analysed as previously described [79].
Briefly, raw sequencing data were de-multiplexed and
aligned using mouse July 2007 assembly (mm9) or
human February 2009 (hg19) as the reference genomes.
Reads located in fragments flanked by two restriction
sites of the same enzyme, or in fragments smaller than
40 bp, were filtered out. Mapped reads were then
converted to reads-per-first-enzyme-fragment-end units
and smoothed using a 30 fragment mean running
window algorithm, uploaded to the UCSC genome
browser [82] (http://genome.ucsc.edu/, 2015) and sub-
jected to a five-pixel smoothing window. In Fig. 7, as reads
upstream of the breakpoint come from both the intact
and translocated PAX3 locus and downstream reads map
to PAX3 or FOXO1, 4C-seq scales have been adjusted to
normalise reads at either side of the translocation.
The protocol of the chromatin modelling based on
4C-seq data was applied as previously described [37].
Briefly, 4C-seq data were used as a proxy of distance
between individual viewpoints and the rest of the DNA
fragments under the assumption that 4C-seq reads are in-
versely proportional to their spatial distance. These dis-
tances were used as restraint coordinates to locate the
position of DNA fragments in the 3D space. The Integra-
tive Modelling Platform (IMP) [83] was used for the gener-
ation of chromatin 3D models. The 200 top-scoring
models were selected out of 50,000 and then clustered in
two populations that were mirror image of each other. The
most populated cluster was selected and used for the cal-
culation of the Virtual Hi-C, as previously described [37].
4C-seq reads corresponding to the derivative t(2:13)
chromosome were duplicated in order to compensate
the theoretical quantity of whole chromosomes depend-
ing on the viewpoint used. Reads were then normalised
and the Z-scores calculated as previously described [37]
to filter out the non-significant data. For peak calling of
4C-seq data, interaction calling was carried out using as
a background a two-sided monotonic regression calcu-
lated using the Pool Adjacent Violators Algorithm
(PAVA) from the R-package isotone [84]. With this back-
ground, we computed the distribution of residuals (dif-
ferences between observed and expected values for each
fragment) and defined as peaks those fragments with re-
siduals that were above the third quartile plus 1.5 × IQR,
IQR being the interquartile range [85]. Peaks less than
500 bp apart were merged together in a single unit.
Directionality index and boundary calling
Boundary calling was carried out using the D.I. [2]. The
D.I. at each position is based on fragments contacts for
both sides, but we only used data limited to these re-
gions of interest. Thus, we are missing data for the
fragments located at the borders. We simulated the
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missing data for the fragments in the borders by taking
the mean value of the complete dataset as reference.
We calculated the D.I. of the Hi-C’s for both loci in the
two species iteratively, changing the expected TAD size
variable in each iteration (Additional file 2: Table S4).
We selected the boundaries that appeared in all the itera-
tions. We used the same approach for the virtual Hi-C of
the truncated locus but we selected the top two boundar-
ies which appeared in 96% of the iterations (Additional file
2: Table S4). Hi-C data were taken from the Epigenome
Browser (http://egg.wustl.edu/d/; 2016); the datasets used
for these calculations were: MM9: Esc_20kb_hindIII_
rep1_mouse and HG19: Esc_20kb_hindIII_rep2_human.
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